FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:790-799 February 22, 2007 Number 8 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Corey, L. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Epidemiologic data suggest that infection with herpes simplex virus type 2 (HSV-2) is associated with increased genital shedding of human immunodeficiency virus type 1 (HIV-1) RNA and HIV-1 transmissibility.

Methods We conducted a randomized, double-blind, placebo-controlled trial of HSV suppressive therapy with valacyclovir (at a dose of 500 mg twice daily) in Burkina Faso among women who were seropositive for HIV-1 and HSV-2; all were ineligible for highly active antiretroviral therapy. The patients were followed for 24 weeks (12 weeks before and 12 weeks after randomization). Regression models were used to assess the effect of valacyclovir on the presence and quantity of genital and plasma HIV-1 RNA and genital HSV-2 DNA during treatment, adjusting for baseline values, and to evaluate the effect over time.

Results A total of 140 women were randomly assigned to treatment groups; 136 were included in the analyses. At enrollment, the median CD4 cell count was 446 cells per cubic millimeter, and the mean plasma viral load was 4.44 log₁₀ copies per milliliter. With the use of summary-measures analysis, valacyclovir therapy was found to be associated with a significant decrease in the frequency of genital HIV-1 RNA (odds ratio, 0.41; 95% confidence interval [CI], 0.21 to 0.80) and in the mean quantity of the virus (log₁₀ copies per milliliter, –0.29; 95% CI, –0.44 to –0.15). However, there was no significant decrease in detection of HIV (risk ratio, 0.93; 95% CI, 0.81 to 1.07). HSV suppressive therapy also reduced the mean plasma HIV-1 RNA level by 0.53 log₁₀ copy per milliliter (95% CI, –0.72 to –0.35). Repeated-measures analysis showed that these effects became significantly stronger during the 3 months of follow-up.

Conclusions HSV suppressive therapy significantly reduces genital and plasma HIV-1 RNA levels in dually infected women. This finding may have important implications for HIV control. (ClinicalTrials.gov number, NCT00158509 [ClinicalTrials.gov] .)

Source Information

From the Centre Muraz (N.N., A.O., I.K., L.V., M.-C.D., D.D., A. Sanon, R.V.) and University Hospital (J.-B.A., A. Sawadogo) — both in Bobo-Dioulasso, Burkina Faso; the London School of Hygiene and Tropical Medicine, London (N.N., H.A.W., P.M.); and Montpellier University Hospital and Research Unit 145, Montpellier, France (V.F., P.B., M.S., P.V.P.).

Address reprint requests to Dr. Nagot at the Clinical Research Unit, London School of Hygiene and Tropical Medicine, Keppel St., London WC1E 7HT, United Kingdom, or at n_nagot{at}hotmail.com.

Full Text of this Article

Related Letters:

HSV Therapy and HIV-1 Reduction
Martinez V., Caumes E., Eisenhut M., Nagot N., Weiss H., Van de Perre P.
Extract | Full Text | PDF  
N Engl J Med 2007; 356:2323-2324, May 31, 2007. Correspondence

This article has been cited by other articles:

• Celum, C., Wald, A., Lingappa, J.R., Magaret, A.S., Wang, R.S., Mugo, N., Mujugira, A., Baeten, J.M., Mullins, J.I., Hughes, J.P., Bukusi, E.A., Cohen, C.R., Katabira, E., Ronald, A., Kiarie, J., Farquhar, C., Stewart, G.J., Makhema, J., Essex, M., Were, E., Fife, K.H., de Bruyn, G., Gray, G.E., McIntyre, J.A., Manongi, R., Kapiga, S., Coetzee, D., Allen, S., Inambao, M., Kayitenkore, K., Karita, E., Kanweka, W., Delany, S., Rees, H., Vwalika, B., Stevens, W., Campbell, M.S., Thomas, K.K., Coombs, R.W., Morrow, R., Whittington, W.L.H., McElrath, M.J., Barnes, L., Ridzon, R., Corey, L., the Partners in Prevention HSV/HIV Transmission St, (2010). Acyclovir and Transmission of HIV-1 from Persons Infected with HIV-1 and HSV-2. NEJM 362: 427-439 [Abstract] [Full Text]  
• Kwant-Mitchell, A., Ashkar, A. A., Rosenthal, K. L. (2009). Mucosal Innate and Adaptive Immune Responses against Herpes Simplex Virus Type 2 in a Humanized Mouse Model. J. Virol. 83: 10664-10676 [Abstract] [Full Text]  
• Bautista, C T, Singer, D E, O'Connell, R J, Crum-Cianflone, N, Agan, B K, Malia, J A, Sanchez, J L, Peel, S A, Michael, N L, Scott, P T (2009). Herpes simplex virus type 2 and HIV infection among US military personnel: implications for health prevention programmes. Int J STD AIDS 20: 634-637 [Abstract] [Full Text]  
• Tchesnokov, E. P., Obikhod, A., Massud, I., Lisco, A., Vanpouille, C., Brichacek, B., Balzarini, J., McGuigan, C., Derudas, M., Margolis, L., Schinazi, R. F., Gotte, M. (2009). Mechanisms Associated with HIV-1 Resistance to Acyclovir by the V75I Mutation in Reverse Transcriptase. J. Biol. Chem. 284: 21496-21504 [Abstract] [Full Text]  
• Magaret, A S, Johnston, C, Wald, A (2009). Use of the designation "shedder" in mucosal detection of herpes simplex virus DNA involving repeated sampling. Sex. Transm. Infect. 85: 270-275 [Abstract] [Full Text]  
• Prichard, M. N., Hartline, C. B., Harden, E. A., Daily, S. L., Beadle, J. R., Valiaeva, N., Kern, E. R., Hostetler, K. Y. (2008). Inhibition of Herpesvirus Replication by Hexadecyloxypropyl Esters of Purine- and Pyrimidine-Based Phosphonomethoxyethyl Nucleoside Phosphonates. Antimicrob. Agents Chemother. 52: 4326-4330 [Abstract] [Full Text]  
• McMahon, M. A., Siliciano, J. D., Lai, J., Liu, J. O., Stivers, J. T., Siliciano, R. F., Kohli, R. M. (2008). The Antiherpetic Drug Acyclovir Inhibits HIV Replication and Selects the V75I Reverse Transcriptase Multidrug Resistance Mutation. J. Biol. Chem. 283: 31289-31293 [Abstract] [Full Text]  
• Mayaud, P, Nagot, N, Konate, I, Ouedraogo, A, Weiss, H A, Foulongne, V, Defer, M-C, Sawadogo, A, Segondy, M, Van de Perre, P, on behalf of the ANRS 1285 Study Group, (2008). Effect of HIV-1 and antiretroviral therapy on herpes simplex virus type 2: a prospective study in African women. Sex. Transm. Infect. 84: 332-337 [Abstract] [Full Text]  
• White, R G, Freeman, E E, Orroth, K K, Bakker, R, Weiss, H A, O'Farrell, N, Buve, A, Hayes, R J, Glynn, J R (2008). Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa. Sex. Transm. Infect. 84: ii12-ii18 [Abstract] [Full Text]  
• Wang, H., Wang, N., Chen, R. Y, Sharp, G. B, Ma, Y., Wang, G., Ding, G., Wu, Z. (2008). Prevalence and predictors of herpes simplex virus type 2 infection among female sex workers in Yunnan Province, China. Int J STD AIDS 19: 635-639 [Abstract] [Full Text]  
• Hook, L. M., Huang, J., Jiang, M., Hodinka, R., Friedman, H. M. (2008). Blocking Antibody Access to Neutralizing Domains on Glycoproteins Involved in Entry as a Novel Mechanism of Immune Evasion by Herpes Simplex Virus Type 1 Glycoproteins C and E. J. Virol. 82: 6935-6941 [Abstract] [Full Text]  
• Mesquita, P. M. M., Wilson, S. S., Manlow, P., Fischetti, L., Keller, M. J., Herold, B. C., Shattock, R. J. (2008). Candidate Microbicide PPCM Blocks Human Immunodeficiency Virus Type 1 Infection in Cell and Tissue Cultures and Prevents Genital Herpes in a Murine Model. J. Virol. 82: 6576-6584 [Abstract] [Full Text]  
• Berger, J. R., Houff, S. (2008). Neurological Complications of Herpes Simplex Virus Type 2 Infection. Arch Neurol 65: 596-600 [Abstract] [Full Text]  
• Watson-Jones, D., Weiss, H. A., Rusizoka, M., Changalucha, J., Baisley, K., Mugeye, K., Tanton, C., Ross, D., Everett, D., Clayton, T., Balira, R., Knight, L., Hambleton, I., Le Goff, J., Belec, L., Hayes, R. (2008). Effect of Herpes Simplex Suppression on Incidence of HIV among Women in Tanzania. NEJM 358: 1560-1571 [Abstract] [Full Text]  
• Gorander, S., Lagergard, T., Romanik, M., Viscidi, R. P., Martirosian, G., Liljeqvist, J.-A. (2008). Seroprevalences of Herpes Simplex Virus Type 2, Five Oncogenic Human Papillomaviruses, and Chlamydia trachomatis in Katowice, Poland. CVI 15: 675-680 [Abstract] [Full Text]  
• Isaacs, C. E., Wen, G. Y., Xu, W., Jia, J. H., Rohan, L., Corbo, C., Di Maggio, V., Jenkins, E. C. Jr., Hillier, S. (2008). Epigallocatechin Gallate Inactivates Clinical Isolates of Herpes Simplex Virus. Antimicrob. Agents Chemother. 52: 962-970 [Abstract] [Full Text]  
• Chentoufi, A. A., Zhang, X., Lamberth, K., Dasgupta, G., Bettahi, I., Nguyen, A., Wu, M., Zhu, X., Mohebbi, A., Buus, S., Wechsler, S. L., Nesburn, A. B., BenMohamed, L. (2008). HLA-A*0201-Restricted CD8+ Cytotoxic T Lymphocyte Epitopes Identified from Herpes Simplex Virus Glycoprotein D. J. Immunol. 180: 426-437 [Abstract] [Full Text]  
• Martinez, V., Caumes, E., Eisenhut, M., Nagot, N., Weiss, H., Van de Perre, P. (2007). HSV Therapy and HIV-1 Reduction. NEJM 356: 2323-2324 [Full Text]  
• (2007). HSV-Suppressive Therapy Might Improve HIV Status in Dually Infected Women. JWatch Women's Health 2007: 4-4 [Full Text]  
• Corey, L. (2007). Synergistic Copathogens -- HIV-1 and HSV-2. NEJM 356: 854-856 [Full Text]  
• (2007). A Tale of Two Viruses: HSV-2 and HIV. JWatch Infect. Diseases 2007: 1-1 [Full Text]